182 filings
Page 5 of 10
8-K
11yw00oi70sv zetm
5 May 21
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021
6:31am
8-K
2ihy1mjk
3 May 21
Entry into a Material Definitive Agreement
7:00am
8-K
n4139 tjn3
27 Apr 21
Departure of Directors or Certain Officers
7:05am
DEFA14A
i2mxyh0v
27 Apr 21
Additional proxy soliciting materials
6:49am
S-8
ma0u9dfekt5wyqh5km8
9 Mar 21
Registration of securities for employees
7:21am
8-K
gg6e9zorx2 o3fy
9 Mar 21
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020
7:07am
8-K
pny wnish
9 Mar 21
Other Events
7:06am
8-K
cwelsvm 7nxr
24 Feb 21
Surface Oncology to Participate in Upcoming March Investor Conferences
7:02am
8-K
t7fr7
11 Feb 21
Surface Oncology to Appoint Robert Ross, M.D., as President and Chief Executive Officer
7:15am
8-K
jhtiid1domtlag3w7g
11 Jan 21
Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference
6:02am
8-K
hc5fr7hfucj
17 Dec 20
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
7:05am
8-K
83ezrrtmdvrovt3
25 Nov 20
Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
7:00am
8-K
wftd1vjcfppb
13 Nov 20
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
7:00am
8-K
jjv hwsxnt
12 Nov 20
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer
6:58am
8-K
q2tpw pycdjul9ms
10 Nov 20
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020
6:02am
8-K
f7b l6a3hg
9 Nov 20
Surface Oncology to Present at the Cowen IO Next Summit
4:01pm
8-K
ohdl9
9 Nov 20
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference
8:00am